When first described, ESR1-e2>CCDC170 in ER+ breast cancer cells led to enhanced growth and reduced sensitivity to tamoxifen (75) suggesting a role for ESR1-e2>CCDC170 in ET resistance. Here, CCDC170 is linked to breast carcinoma.